HCC

Results from the phase 2 LTHAIC study showed that adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib achieved robust and durable responses in patients with advanced hepatocellular carcinoma.

In an interview with Targeted Oncology, Thomas Marron, MD, PhD, discussed neoadjuvant cemiplimab for the treatment of hepatocellular carcinoma.

The FDA’s Oncologic Drug Advisory Committee voted 5 to 4 against the continued accelerated approval of nivolumab for the treatment of patients with hepatocellular carcinoma who were previously treated with sorafenib.

In an 8 to 0 vote, the FDA’s Oncologic Drug Advisory Committee opted to continue to accelerated approval of pembrolizumab for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

In the past 3 years, the FDA has approved 7 novel drugs, either given alone or in combination, to help treat patients with hepatocellular carcinoma.

Half of all patients with hepatocellular carcinoma treated with the combination of regorafenib and nivolumab following progression on 2 lines of chemotherapy achieved disease control, according to initial results from a phase 2 proof-of-concept trial.

In a single-arm study, 100% of patients treated with sintilimab plus stereotactic body radiotherapy who had oligometastases of hepatocellular carcinoma achieved disease control and were alive and progression free at 6 months.

The FDA has approved TheraSphere yttrium-90 glass microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

In an interview with Targeted Oncology, Laura Goff, MD, discussed the treatment of hepatocellular carcinoma in the frontline and beyond.

As part of the virtual 17th Annual Meeting of the International School of Gastrointestinal Oncology, a debate ensued around whether liver-directed or systemic therapy is best for the treatment of patients with HCC.

Ruth He, MD, acknowledges the current struggles experts face in combatting unresectable hepatocellular carcinoma.

Ruth He, MD, discusses the approval of frontline atezolizumab-bevacizumab and its relation to subsequent treatment of patients with unresectable hepatocellular carcinoma.

Ruth He, MD, discusses major takeaways from the phase 3 IMbrave150 trial of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

Ruth He, MD, highlights factors that influence her use of frontline systemic therapy in patients with unresectable hepatocellular carcinoma.

Ruth He, MD, discusses the current treatment options for unresectable hepatocellular carcinoma.

Preliminary data showing the neoadjuvant use of cabozantinib and nivolumab to be feasible for borderline resectable patients with hepatocellular carcinoma that can lead to potentially curative resection.

Al B. Benson, MD, discusses concerns in the hepatocellular carcinoma setting for treating patients for the best outcomes.

Good responses to lenvatinib were observed in patients with hepatocellular carcinoma who maintained a high relative dose intensity of 75% or greater.

Although lenvatinib has shown antitumor effects in hepatocellular carcinoma, long-term safety data are lacking.

The FDA has granted an Orphan Drug Designation to the novel small molecule chemotherapeutic uttroside-B for the treatment of patients with hepatocellular carcinoma.

Pembrolizumab monotherapy demonstrated durable antitumor activity and encouraging effects on survival in an evaluation of patients with previously untreated hepatocellular carcinoma.

In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.

Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.

Ghasson K. Abou-Alfa, MD, discusses the rapid evolution observed in the treatment landscape of hepatocellular carcinoma over the last few years.

Andrew X. Zhu, MD, PhD, discusses the evolving treatment landscape for patients with hepatocellular carcinoma.